...
首页> 外文期刊>International Journal of Pharmaceutics >Denatured globular protein and bile salt-coated nanoparticles for poorly water-soluble drugs: Penetration across the intestinal epithelial barrier into the circulation system and enhanced oral bioavailability
【24h】

Denatured globular protein and bile salt-coated nanoparticles for poorly water-soluble drugs: Penetration across the intestinal epithelial barrier into the circulation system and enhanced oral bioavailability

机译:水溶性差的药物的变性球状蛋白和胆汁盐包裹的纳米颗粒:穿过肠上皮屏障渗透进入循环系统并增强口服生物利用度

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Oral drug delivery is the most preferred route for patients; however, the low solubility of drugs and the resultant poor absorption compromise the benefits of oral administration. On the other hand, for years, the overwhelmingly accepted mechanism for enhanced oral absorption using lipid nanocarriers was based on the process of lipid digestion and drug solubilization in the small intestine. Few reports indicated that other bypass pathways are involved in drug absorption in the gastrointestinal tract (GIT) for oral delivery of nanocarriers. Herein, we report a new nanoemulsion system with a denatured globular protein with a diameter of 30 nm, soybean protein isolates (SPI), and bile salt as emulsifiers, aiming to enhance the absorption of insoluble drugs and explore other pathways for absorption. A BCS class II drug, fenofibrate (FB), was used as the model drug. The SPI and bile salt-coated Ns with a diameter of approximately 150 nm were prepared via a high-pressure homogenizing procedure. Interestingly, the present Ns could be converted to solid dosage form using fluid-bed coating technology, maintaining a nanoscale size. Most importantly, in a model of in situ rat intestinal perfusion, Ns could penetrate across the intestinal epithelial barrier into the systemic circulation and then obtain biodistribution into other tissues. In addition, Ns significantly improved FB oral absorption, exhibited as a greater than 2- and 2.5-fold increase in C-max and AUC(0 t), respectively, compared to the suspension formulation. Overall, the present Ns are promising nanocarriers for the oral delivery of insoluble drugs, and the penetration of intact Ns across the GIT barrier into systemic circulation may be a new strategy for improved drug absorption with the use of nanocarriers. (C) 2015 Elsevier B.V. All rights reserved.
机译:口服药物输送是患者最优选的途径。然而,药物的低溶解度和由此导致的吸收差损害了口服给药的益处。另一方面,多年来,使用脂质纳米载体增强口服吸收的公认机制是基于小肠中脂质消化和药物增溶的过程。很少有报道表明其他旁路途径与胃肠道(GIT)的药物吸收有关,用于口服纳米载体。本文中,我们报道了一种新的纳米乳液系统,该系统具有直径为30 nm的变性球状蛋白,大豆分离蛋白(SPI)和胆汁盐作为乳化剂,旨在增强不溶性药物的吸收并探索其他吸收途径。 BCS II类药物非诺贝特(FB)被用作模型药物。通过高压均质程序制备直径约为150 nm的SPI和胆盐盐包被的Ns。有趣的是,本发明的Ns可以使用流化床包衣技术转化为固体剂型,并保持纳米级尺寸。最重要的是,在原位大鼠肠灌注模型中,Ns可以穿过肠上皮屏障进入体循环,然后在其他组织中获得生物分布。另外,与悬浮液制剂相比,Ns显着改善了FB口服吸收,分别显示C-max和AUC(0 t)分别大于2倍和2.5倍。总体而言,目前的Ns是用于口服递送不溶性药物的有前途的纳米载体,而完整的Ns穿过GIT屏障渗透到全身循环中可能是使用纳米载体改善药物吸收的新策略。 (C)2015 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号